Clinical review report: Buprenorphine extended-release injection (Sublocade) (Indivior Canada, Ltd.) indication : for the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product

The objective of this report was to perform a systematic review of the beneficial and harmful effects of buprenorphine extended-release injection (BUP-ER) 100 mg and 300 mg for the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health July 2019, 2019
Edition:	Version: final
Series:	CADTH common drug review
Subjects:	Adult Canada Buprenorphine / Therapeutic Use Delayed-action Preparations / Administration & Dosage Injections Opioid-related Disorders / Drug Therapy Treatment Outcome Buprenorphine / Administration & Dosage
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK546457
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa